Completed PHASE3 INTERVENTIONAL NCT00034879

Iressa Expanded Access Program (EAP)

An Expanded Access Clinical Program With ZD1839 (IRESSA®) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Sponsor: AstraZeneca

Conditions Carcinoma Metastases Neoplasm Non-small-cell Lung

Updated 7 times since 2017 Last updated: Jan 3, 2013 Started: Aug 31, 2000 Primary completion: Oct 31, 2003 Completion: Oct 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Carcinoma and Metastases, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Abilene, United States , Abington, United States , Akron, United States , Alabaster, United States , Albany, United States , Albuquerque, United States , Alexandria, United States , Allentown, United States , Amarillo, United States and 586 more locations